Floatz logo

2-HYDROXYOLEIC ACID (SODIUM SALT)

High-grade Glioma

Laminar PharmaceuticalsSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

108 Active assets in the High-grade Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

2-HYDROXYOLEIC ACID (SODIUM SALT) is also rated in:

glioblastomaDormant
B
Indicative ·
60 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
Solid Tumor, Unspecified, ChildDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →